著者

Wakaba Fukushima Megumi Hara Yuri Kitamura Masahiko Shibata Yoshikazu Ugawa Koichi Hirata Akira Oka Shinya Miyamoto Susumu Kusunoki Satoshi Kuwabara Shuji Hashimoto Tomotaka Sobue

出版者

Japan Epidemiological Association

雑誌

Journal of Epidemiology (ISSN:09175040)

巻号頁・発行日

vol.32, no.1, pp.34-43, 2022-01-05 (Released:2022-01-05)

参考文献数

50

被引用文献数

8

---

Background: Since June 2013, Japan has suspended proactive recommendation of human papillomavirus (HPV) vaccination due to self-reported diverse symptoms, including pain and motor dysfunction, as possible serious adverse events following immunization. Although these symptoms may be seen in adolescents without HPV vaccination, their frequency, taking into account disease severity, has not been examined.Methods: A two-stage, descriptive, nationwide epidemiological survey was conducted in 2016, with a 6-month target period from July 1 to December 31, 2015, to estimate the prevalence and incidence of diverse symptoms among Japanese adolescents without HPV vaccination. Participants were 11,037 medical departments in hospitals selected nationwide by stratified random sampling. Eligible patients had to satisfy four criteria: (1) aged 12–18 years upon visiting hospital; (2) having at least one of four symptoms/disorders (pain or sensory dysfunction, motor dysfunction, autonomic dysfunction, or cognitive impairment); (3) symptoms/disorders persisting for at least 3 months; and (4) both criteria (2) and (3) influence attendance at school or work. We then extracted data of patients with diverse symptoms similar to those after HPV vaccination while considering opinions of doctors in charge.Results: Estimated 6-month period prevalence of diverse symptoms among girls aged 12–18 years without HPV vaccination was 20.2 per 100,000. Annual incidence was estimated to be 7.3 per 100,000.Conclusion: Adolescent Japanese girls without HPV vaccination also visited hospitals with diverse symptoms similar to those following HPV vaccination. Our findings predict the medical demands for coincident diverse symptoms, which are temporally associated with but not caused by HPV vaccination of Japanese adolescents.

著者

Tatsuo Shimura Masahiko Shibata Kenji Gonda Takahiro Nakajima Shun Chida Masaru Noda Satoshi Suzuki Izumi Nakamura Keiichi Nakano Toshihiko Fukushima Shinichi Suzuki Seiichi Takenoshita

出版者

日本癌病態治療研究会

雑誌

Annals of Cancer Research and Therapy (ISSN:13446835)

巻号頁・発行日

vol.24, no.1, pp.35-40, 2016-01-13 (Released:2016-03-31)

参考文献数

40

被引用文献数

2

---

Background and Aims: Several investigators have reported the significance of circulating galectin-3 in thyroid cancer patients. However, the precise meaning of circulating galectin-3 remains unclear. The aim of this study was to investigate the relationships between serum galectin-3 levels and angiogenetic factors, and nutritional and inflammatory indicators in patients with thyroid cancer. Materials and Methods: Sixty-one patients with thyroid tumors were enrolled, comprising 47 pre-treatment thyroid cancer patients and 14 patients with benign thyroid diseases. Galectin-3, interleukin (IL)-6, vascular endothelial growth factor, granulocyte colony-stimulating factor (G-CSF), soluble form of intercellular adhesion molecule-1 (sICAM-1), retinol binding protein, prealbumin, albumin, and transferrin were measured. C-reactive protein (CRP), neutrophil count, lymphocyte count, and neutrophil/lymphocyte ratio (NLR) were also investigated. Results: The amounts of circulating galectin-3 in benign disease and thyroid cancer were significantly higher than those of healthy volunteers (P < 0.001). Analysis of galectin-3 performance in distinguishing malignant disease from benign disease using a receiver operating characteristic curve revealed that the area under the curve was 0.555. There were statistically significant correlations between the circulating amount of galectin-3 and IL6, G-CSF, and sICAM-1. Serum galectin-3 showed statistically significant correlations with albumin, prealbumin, and transferrin. Circulating galectin-3 exhibited strong correlations with CRP, neutrophil count, lymphocyte count, and NLR. Conclusions: Galectin-3 may be one of the key factors in the regulation of angiogenesis, inflammation, and nutrition.

著者

Kosaku Mimura Leo Yamada Daisuke Ujiie Suguru Hayase Takeshi Tada Hiroyuki Hanayama Aung Kyi Thar Min Masahiko Shibata Tomoyuki Momma Zenichiro Saze Shinji Ohki Koji Kono

出版者

THE FUKUSHIMA SOCIETY OF MEDICAL SCIENCE

雑誌

FUKUSHIMA JOURNAL OF MEDICAL SCIENCE (ISSN:00162590)

巻号頁・発行日

pp.2018-09, (Released:2018-07-27)

参考文献数

48

被引用文献数

27

---

Cancer vaccines and immune checkpoint inhibitors (ICI) have recently been employed as immunotherapies for esophageal squamous cell carcinoma (ESCC). Cancer vaccines for ESCC have yielded several promising results from investigator-initiated phase I and II clinical trials. Furthermore, a Randomized Controlled Trial as an adjuvant setting after curative surgery is in progress in Japan. On the other hand, ICI, anti-CTLA-4 mAb and anti-PD-1 mAb, have demonstrated tumor shrinkage and improved overall survival in patients with multiple cancer types. For ESCC, several clinical trials using anti-PD-1/anti-PD-L1 mAb are underway with several recent promising results. In this review, cancer vaccines and ICI are discussed as novel therapeutic strategies for ESCC.

著者

IZUMI NAKAMURA MASASHI KANAZAWA YU SATO ATSUSHI IRISAWA TADAYUKI TAKAGI TAKASHI OGATA SHOGO KASHIMURA AKIRA KENJO HIROYUKI SUZUKI MASAHIKO SHIBATA TATSUO SHIMURA HIROMASA OHIRA MITSUKAZU GOTO SEIICHI TAKENOSHITA HITOSHI OHTO

出版者

福島医学会

雑誌

FUKUSHIMA JOURNAL OF MEDICAL SCIENCE (ISSN:00162590)

巻号頁・発行日

vol.58, no.1, pp.40-48, 2012 (Released:2012-06-28)

参考文献数

25

被引用文献数

4 7 5

---

Dendritic cells (DCs) are powerful antigen-presenting cells (APCs) that have attracted attention in recent years from the viewpoint of DC vaccine therapy against cancer. However, the existence of a strongly immunosuppressed state in cancer-bearing individuals inhibits DC maturation, which is one of the problems facing anti-cancer DC vaccine therapy. Isolated DCs loaded with tumor antigen ex vivo and administered as a cellular vaccine have been found to induce protective and therapeutic anti-tumor immunity in experimental animals. In clinical trials of DC vaccination for cancer patients, induction of anti-tumor immune responses and tumor regression has been observed. In this study, eighty-one advanced cancer patients unsuccessfully treated by established treatment in individual cases were selected between January 2002 and May 2007 at Fukushima Medical University. The usefulness of DC therapy was investigated by intradermal injection of peptide pulsed DCs for an overall objective response rate of 28.0%. Furthermore, direct injection of immature DCs into tumor extracted an overall objective response rate of 35.7%, and especially 40.0% for advanced pancreatic cancer by using endoscopic ultrasound-guided fine-needle injection technique as a novel approach. These results indicate that DC-based vaccination could be a promising treatment modality for various cancers, however multiple hurdles must be cleared before the development of an affordable DC-based vaccination can be used worldwide.